Navigation Links
A New Era Of Hope For Neglected Diseases

After a barren period when very few therapies were introduced for neglected diseases, which kill around 3m people a year and cause the loss of the equivalent of 92m years' of healthy life, there are now over 60 drug research projects underway.

In the PLoS Medicine analysis, which is based upon a 100-page report financed by the Wellcome Trust, Mary Moran of the London School of Economics found that around three-quarters of these projects are conducted under the umbrella of drug development Public-Private Partnerships (PPPs). Thirteen of them have already reached clinical trial stage and two are awaiting regulatory approval (rectal artesunate for malaria, and paromomycin for visceral leishmaniasis). These PPP-driven projects should result in six or seven new drug registrations in the next five years.

Research by Dr Moran and her colleagues has shown that PPPs have been a critical driver of this considerable increase in activity, and that the PPP approach brings together the best skills of both public and private partners. This model consequently performs better than either sector working alone when it comes to delivering safe, effective, affordable drugs for neglected diseases.

In a linked editorial, entitled "A New Era of Hope for the World's Most Neglected Diseases", the PLoS Medicine editors argue that Moran's findings are one of several indicators that the world is finally taking action against these diseases.

For example, the Gleneagles Communiqué arising out of this year's G8 summit specifically called for increased investment to encourage the development of tools for neglected-disease control.

Citation: Moran M (2005) A breakthrough in R&D for neglected diseases: New ways to get the drugs we need. PLoS Med 2(9): e302.
http:/?​dx.doi.org/?0.1371/​journal.pmed.0020302


'"/>

Source:PLoS


Page: 1

Related biology news :

1. A New Era of Hope for the Worlds Most Neglected Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Era Hope For Neglected Diseases

(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... by scientists at McGill University and the University of Zurich ... their ability to signal information. The research may explain why ... a specially formulated diet. The findings, published Jan. 16 ... processes that inhibit brain activity, such as that involved in ...
... This news release is available in French ... 2014 When it comes to global warming, there are seven ... the United Kingdom. A new study published in Environmental Research ... than 60 per cent of pre-2005 global warming. Uniquely, it also ...
... 15, 2014 MedNet Solutions , a global life ... pleased to announce that the latest version of ... iMedNet user community.  iMedNet EDC provides an ... to Sponsors and CROs wanting to quickly and easily build ...
Cached Biology News:How metabolism and brain activity are linked 2Global warming's biggest offenders 2MedNet Solutions Announces Latest Release Of Its Innovative iMedNet EDC eClinical Solution 2
(Date:5/27/2015)... 2015  Ceres, Inc. (Nasdaq: CERE ), an ... for a genetic sequence derived from soybean, covering uses ... development and plant transformation. The company believes that its ... are the target of a class of commercial herbicides. ... license to the innovation, including an opportunity for exclusivity ...
(Date:5/26/2015)... OTTAWA, Canada, and BELLINGHAM, Washington, USA (PRWEB) May 26, ... has signed a formal partnership with the ... Ottawa Centre for Extreme and Quantum Photonics. The center ... in the field of photonics, and will be only ... Arthurs, CEO of SPIE, the international society for ...
(Date:5/26/2015)... and HILDEN, Germany ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... its QIAGEN Clinical Insight ® (QCI™) bioinformatics ... to interpret and report on genomic variants identified ... applications for the bioinformatics platform are in oncology, ...
(Date:5/26/2015)... Global Stem Cells Group and ... company’s first cellular and regenerative medicine symposium in Barcelona ... hands-on stem cell training class Oct. 10. The event ... President of Therapeutic Confrontations (CONFTERA) in Barcelona. , ... regenerative medicine and recent advances in cellular therapies, Global ...
Breaking Biology Technology:Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3
... use, reliability and ... convenience, ... availability of easypod(R), the first of its kind,automated device in the ... [somatropin (rDNA origin) for,injection], the company,s treatment for growth hormone deficiency. ...
... proteins in their natural environment and interactions inside ... advanced microscopy technique called cryo-electron tomography, researchers from ... proteins responsible for cell-cell contacts for the first ... publish the first 3D image of human skin ...
... (NYSE: SGP ) was honored by Scrip ... industry awards: Large Pharma Company,of the Year, Management ... Year for,Fred Hassan, Schering-Plough chairman and CEO., ... and achievement,within the pharmaceutical and biotech industries. Scrip ...
Cached Biology Technology:Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device 2Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device 3Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device 4The closest look ever at native human tissue 2Schering-Plough Wins Three of Scrip's Top Pharma Industry Awards 2
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Human Siglec-9 Biotinylated Affinity Purified Pab...
Biology Products: